Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Moby Intelligence

Tue, February 24, 2026 astatine 11:32 AM CST 3 min read

• Delivered $450 cardinal successful full-year nett income for 2025, establishing XDEMVY arsenic a breakout therapeutic and the institution arsenic a person successful oculus care.

• Achieved profitability astatine the merchandise enactment level for XDEMVY, providing fiscal flexibility to reinvest successful high-return maturation drivers.

• Expanded the addressable marketplace absorption beyond the archetypal 9 cardinal patients to the afloat 25 cardinal Americans with Demodex blepharitis arsenic screening becomes routine.

• Attributed commercialized occurrence to a 'repeatable playbook' that identifies diseases with wide basal causes and applies proven improvement and commercialized frameworks.

• Observed a cardinal displacement successful signifier behaviour wherever oculus attraction professionals are present screening for the illness crossed broader diligent types, including those with glaucoma and styes.

• Reported that direct-to-consumer consciousness reached 25% among surveyed patients, importantly expanding the measurement of patients proactively requesting the attraction by name.

• Projected 2026 nett merchandise income betwixt $670 cardinal and $700 million, representing astir 50% yearly maturation astatine the midpoint.

• Anticipated first-quarter gross to beryllium level to somewhat beneath Q4 2025 owed to emblematic manufacture seasonality, including deductible resets and upwind disruptions.

• Planned a targeted enlargement of the income unit by 15 to 20 cardinal relationship leaders to deepen utilization wrong high-opportunity aesculapian practices.

• Committed to initiating a Phase II proceedings for TP-05 successful Lyme illness prevention successful Q2 2026, targeting a Phase III-ready bundle by 2027.

• Maintained a semipermanent gross-to-net discount people of 43% to 45%, with expectations to scope this scope by mid-2026 aft Q1 seasonal pressure.

• Initiated the first-ever Phase II proceedings for TP-04 successful Ocular Rosacea, a imaginable blockbuster class with nary presently approved FDA treatments.

• Confirmed that the FDA does not necessitate a 'cure' for Ocular Rosacea endpoints, but alternatively a demonstrated betterment successful redness and inflammation.

• Allocated $25 cardinal to $30 cardinal for the TP-05 Lyme illness trial, reflecting the standard required for a prophylactic programme successful a high-risk population.

• Highlighted the assignment of David Pyott, erstwhile Allergan CEO, to the Board to enactment the modulation into a large-scale planetary oculus attraction franchise.

Our analysts conscionable identified a banal with the imaginable to beryllium the adjacent Nvidia. Tell america however you put and we'll amusement you wherefore it's our #1 pick. Tap here.